Clinical Trials

Our Clinical Cancer Trials

Capital Health Cancer Center participates in many National Cancer Institute (NCI), university and pharmaceutical phase II and III clinical trials. Some studies lead to the discovery of new methods to detect and diagnose cancer, while others focus on innovative treatments before they become widely available.

Clinical trials offer patients the very latest in cancer care while giving physicians and researchers the opportunity to study the effectiveness of the treatment. Participation is entirely voluntary.

Our experienced oncologists and research nurses carefully review study criteria, potential benefits, risks, and other considerations with eligible patients for enrollment into a clinical study. Once enrolled, our Clinical Research Department staff carefully monitors patients throughout the research trial and is available to answer questions.

The National Cancer Institute has a brochure Taking Part in Cancer Treatment Research Studies to help you understand the details of clinical trials.

To learn more about our ongoing trials for cancer treatment and prevention, please contact Tina Bergner, RN, BSN, OCN, oncology clinical research coordinator, at 609-537-7042 or e-mail her at [email protected] for more information.

Active clinical trials currently being offered:

Brain studies

NRG-BN003: Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma.

Breast studies

NRG BR-003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High Risk Node-Negative Triple-Negative Invasive Breast Cancer

Post-Mastectomy ROM Study (Dr. Lisa Allen): Comparison of Upper Extremity Range of Motion in Post-Mastectomy Patients with and without formal mobility exercise education and initiation at time of mastectomy

Rutgers Cancer Institute of New Jersey: African American Woman’s Circle of Health Breast Cancer Research Study

MATCH studies

EAY131: Molecular Analysis for Therapy Choice (MATCH) – Patients enrolled in study will have a tumor biopsy for molecular characterization and those with molecular variants addressed by treatments included in the trial will be offered treatment. Patients with hystologically documented solid tumors and lymphomas whose disease has progressed following at least one line of standard systemic therapy or for whom no standard therapy exists will be registered on the screening step to undergo tumor biopsy and analysis.

Pancreas studies

A021501: Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas

Non-NCI Open Oncology Studies

Capital Health Radiation Oncology Studies: Establishing an anticipatory model for anxiety and depression through a screening tool for first time radiation oncology patients (Rona Remstein)

Clinical Genomics NOVA: Evaluation of the performance of the clinical genomics colvera test in the detection of disease recurrence in patients diagnosed with colorectal cancer – “NOVA” (Drs. Kalina and Schaebler)

Dana-Faber/Brigham and Woman’s Cancer Center (Dr. Geoffrey Oxnard): INHERIT EGFR (Genetic Mutation T790M Lung Registry Study) is a study that aims to identify non-smoking lung cancer patients who have a rare EGFR mutation, called T790M, in the germline

National Evidence-Based Oncology Navigation Metrics: Multisite exploratory study to demonstrate value and sustainability of oncology navigation programs (Patricia Tatrai)